FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034278375> ?p ?o ?g. }

• W2034278375 endingPage "459" @default.
• W2034278375 startingPage "453" @default.
• W2034278375 abstract "New therapies are needed to improve the prognosis of patients with metastatic melanoma. This study evaluates the safety and efficacy of weekly paclitaxel in patients with metastatic melanoma. Patients received paclitaxel at 80 mg/m2 over 1 h, weekly for 3 weeks, followed by a 1-week rest period. Disease status was assessed every other cycle. Treatment was continued until patients experienced either disease progression or unacceptable toxicity. Twenty-seven patients were enrolled in this phase II clinical trial. Of these patients, two were subsequently determined to be ineligible. All patients, however, were considered to be evaluable for toxicity and all patients were included for response assessment in an intention-to-treat analysis. Patients received paclitaxel for a median of two cycles (range, <1–8). None of the 27 patients showed a response to treatment. Eight patients had stable disease. The median progression-free survival was 1.8 months (95% confidence interval, 1.7–2.5 months) and the median survival was 7.6 months (95% confidence interval, 4.7–9.7 months). The most common grade 3 toxicity was neutropenia (four patients) and one patient had grade 4 neutropenia. Other treatment-related grade 3 toxicities included hypersensitivity reaction (one patient) and diarrhoea (one patient). Of note, five patients had peripheral neuropathy; however, in each case, the neuropathy was only grade 1. Weekly paclitaxel is relatively well tolerated and can maintain disease stability for some metastatic melanoma patients. Unfortunately, the anti-tumour activity of this single-agent therapy is low and additional treatment innovations are needed." @default.
• W2034278375 created "2016-06-24" @default.
• W2034278375 creator A5001986524 @default.
• W2034278375 creator A5002082310 @default.
• W2034278375 creator A5021659344 @default.
• W2034278375 creator A5033803656 @default.
• W2034278375 creator A5034081251 @default.
• W2034278375 creator A5035289394 @default.
• W2034278375 creator A5050219951 @default.
• W2034278375 creator A5090262839 @default.
• W2034278375 date "2005-10-01" @default.
• W2034278375 modified "2023-09-27" @default.
• W2034278375 title "Phase II trial of weekly paclitaxel in patients with advanced melanoma" @default.
• W2034278375 cites W1880426265 @default.
• W2034278375 cites W1934698255 @default.
• W2034278375 cites W1946819517 @default.
• W2034278375 cites W1947624718 @default.
• W2034278375 cites W1997919830 @default.
• W2034278375 cites W2008793220 @default.
• W2034278375 cites W2011447881 @default.
• W2034278375 cites W2043660086 @default.
• W2034278375 cites W2053026268 @default.
• W2034278375 cites W2057157978 @default.
• W2034278375 cites W2058979413 @default.
• W2034278375 cites W2096102243 @default.
• W2034278375 cites W2131365547 @default.
• W2034278375 cites W2243915795 @default.
• W2034278375 cites W4255762755 @default.
• W2034278375 doi "https://doi.org/10.1097/00008390-200510000-00015" @default.
• W2034278375 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16179874" @default.
• W2034278375 hasPublicationYear "2005" @default.
• W2034278375 type Work @default.
• W2034278375 sameAs 2034278375 @default.
• W2034278375 citedByCount "34" @default.
• W2034278375 countsByYear W20342783752012 @default.
• W2034278375 countsByYear W20342783752013 @default.
• W2034278375 countsByYear W20342783752014 @default.
• W2034278375 countsByYear W20342783752015 @default.
• W2034278375 countsByYear W20342783752016 @default.
• W2034278375 countsByYear W20342783752017 @default.
• W2034278375 countsByYear W20342783752019 @default.
• W2034278375 countsByYear W20342783752020 @default.
• W2034278375 countsByYear W20342783752023 @default.
• W2034278375 crossrefType "journal-article" @default.
• W2034278375 hasAuthorship W2034278375A5001986524 @default.
• W2034278375 hasAuthorship W2034278375A5002082310 @default.
• W2034278375 hasAuthorship W2034278375A5021659344 @default.
• W2034278375 hasAuthorship W2034278375A5033803656 @default.
• W2034278375 hasAuthorship W2034278375A5034081251 @default.
• W2034278375 hasAuthorship W2034278375A5035289394 @default.
• W2034278375 hasAuthorship W2034278375A5050219951 @default.
• W2034278375 hasAuthorship W2034278375A5090262839 @default.
• W2034278375 hasConcept C126322002 @default.
• W2034278375 hasConcept C134018914 @default.
• W2034278375 hasConcept C141071460 @default.
• W2034278375 hasConcept C2776694085 @default.
• W2034278375 hasConcept C2777063308 @default.
• W2034278375 hasConcept C2777292972 @default.
• W2034278375 hasConcept C2777658100 @default.
• W2034278375 hasConcept C2779901536 @default.
• W2034278375 hasConcept C29730261 @default.
• W2034278375 hasConcept C44249647 @default.
• W2034278375 hasConcept C502942594 @default.
• W2034278375 hasConcept C535046627 @default.
• W2034278375 hasConcept C555293320 @default.
• W2034278375 hasConcept C71924100 @default.
• W2034278375 hasConcept C90924648 @default.
• W2034278375 hasConceptScore W2034278375C126322002 @default.
• W2034278375 hasConceptScore W2034278375C134018914 @default.
• W2034278375 hasConceptScore W2034278375C141071460 @default.
• W2034278375 hasConceptScore W2034278375C2776694085 @default.
• W2034278375 hasConceptScore W2034278375C2777063308 @default.
• W2034278375 hasConceptScore W2034278375C2777292972 @default.
• W2034278375 hasConceptScore W2034278375C2777658100 @default.
• W2034278375 hasConceptScore W2034278375C2779901536 @default.
• W2034278375 hasConceptScore W2034278375C29730261 @default.
• W2034278375 hasConceptScore W2034278375C44249647 @default.
• W2034278375 hasConceptScore W2034278375C502942594 @default.
• W2034278375 hasConceptScore W2034278375C535046627 @default.
• W2034278375 hasConceptScore W2034278375C555293320 @default.
• W2034278375 hasConceptScore W2034278375C71924100 @default.
• W2034278375 hasConceptScore W2034278375C90924648 @default.
• W2034278375 hasIssue "5" @default.
• W2034278375 hasLocation W20342783751 @default.
• W2034278375 hasLocation W20342783752 @default.
• W2034278375 hasOpenAccess W2034278375 @default.
• W2034278375 hasPrimaryLocation W20342783751 @default.
• W2034278375 hasRelatedWork W144459321 @default.
• W2034278375 hasRelatedWork W2137253585 @default.
• W2034278375 hasRelatedWork W2373096389 @default.
• W2034278375 hasRelatedWork W2391421535 @default.
• W2034278375 hasRelatedWork W2396672633 @default.
• W2034278375 hasRelatedWork W2969368401 @default.
• W2034278375 hasRelatedWork W3031924278 @default.
• W2034278375 hasRelatedWork W3087265299 @default.
• W2034278375 hasRelatedWork W4295812906 @default.
• W2034278375 hasRelatedWork W2466982274 @default.
• W2034278375 hasVolume "15" @default.

• next